CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...

proactiveinvestors.com - 2026-07-14 07:53:00

Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...

proactiveinvestors.com - 2026-07-14 07:20:00

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector. The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.

proactiveinvestors.com - 2026-07-13 15:18:27

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-Label Clinical Trial,” has been published in The Journal of Clinical Psychiatry (DOI: 10.4088/JCP.25m16284).

globenewswire.com - 2026-06-04 07:00:00

GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the rapid onset and short psychedelic experience duration offered by GH001 are compelling it remains to be seen how the drug stacks up against peers under real-world conditions.

seekingalpha.com - 2026-05-20 04:07:05

GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.

benzinga.com - 2026-05-15 10:58:23

Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Updates Scientific Presentations and Publications In March 2026, the results of our Phase 2b trial in TRD (GH001-TRD-201) were published in JAMA Psychiatry.

globenewswire.com - 2026-05-14 07:00:00

DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross proceeds of approximately $117.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares are being offered by GH Research PLC.

globenewswire.com - 2026-04-29 08:00:00

FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...

proactiveinvestors.com - 2026-04-21 09:48:00

DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness.

globenewswire.com - 2026-04-20 09:00:00

Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews

feeds.benzinga.com - 2026-04-20 08:35:35

Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...

proactiveinvestors.com - 2026-04-20 05:56:00

Prenetics Global (NASDAQ: PRE - Get Free Report) and GH Research (NASDAQ: GHRS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability. Analyst Ratings This is a summary of

defenseworld.net - 2026-04-15 04:27:19